OpenBusiness & Startups· Tier A · dated & mechanical
Ipsen-acquired Cartos Therapeutics will report phase three myelofibrosis trial data in 2027.
On Biotech Hangout · unverified speaker · Biotech Hangout · Jul 10, 2026 “Cartos, in myelofibrosis, which is in phase three with data expected in 2027.”
→ Read the source episode
Our resolution criterion
disputableCartos myelofibrosis phase three trial data is publicly reported or announced
Target: Dec 31, 2027Dispute this More from Biotech Hangout
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.